Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for sleep disordered breathing in heart failure
NCT04640493Phase 2Withdrawn
- Sponsor
- Columbia University
- Start
- Dec 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in sleep disordered breathing (SDB), sponsored by Columbia University. Planned start Dec 2023; status: withdrawn.
02
Drugs
dapagliflozin
03
Conditions
sleep disordered breathing (SDB)
Beyond the preview
Go deeper on NCT04640493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04640493.